Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of Kylo-11 in ASCVD patients with elevated lipoprotein(a)
CTR20254085Phase 2Active
- Sponsor
- Kylonova Biopharma
- Start
- Oct 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of KYLO-11 in lipoprotein(a) hyperlipoproteinemia (Lp(a)), atherosclerotic disease, sponsored by Kylonova Biopharma. Started Oct 2025; status: active.
02
Drugs
KYLO-11
03
Conditions
lipoprotein(a) hyperlipoproteinemia (Lp(a))atherosclerotic disease
Beyond the preview
Go deeper on CTR20254085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254085.